PDF herunterladen
CC BY 4.0 · Arq Neuropsiquiatr 2025; 83(01): s00441793935
DOI: 10.1055/s-0044-1793935
Original Article

Dosage of botulinum toxin in patients undergoing treatment for hemifacial spasm: is there modification during follow-up?

Fátima de Menezes Dantas 
1   Universidade Federal do Rio Grande do Norte, Centro de Ciências da Saúde, Natal RN, Brazil.
,
Felipe Olobardi Freire 
1   Universidade Federal do Rio Grande do Norte, Centro de Ciências da Saúde, Natal RN, Brazil.
,
Agábio Diógenes Pessoa Neto 
2   Instituto de Ensino e Pesquisa Alberto Santos Dumont, Ambulatório Multiprofissional de Doença de Parkinson, Macaíba RN, Brazil.
,
Clécio de Oliveira Godeiro Júnior 
3   Universidade Federal do Rio Grande do Norte, Hospital Universitário Onofre Lopes, Serviço de Neurologia, Natal RN, Brazil.
,
Rodrigo Alencar e Silva 
3   Universidade Federal do Rio Grande do Norte, Hospital Universitário Onofre Lopes, Serviço de Neurologia, Natal RN, Brazil.
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Background The movement disorder known as hemifacial spasm is characterized by involuntary contractions of the muscles that are innervated by the facial nerve. The treatment of choice for this condition is botulinum toxin injections.

Objective To analyze the botulinum toxin dosage in patients undergoing treatment for hemifacial spasm during a 14-year period.

Methods A retrospective study of medical records from patients treated at the Neurology Service of Hospital Universitário Onofre Lopes, Universidade Federal do Rio Grande do Norte, from 2010 to 2024, was performed.

Results A total of 151 patients met the inclusion criteria. The dose of botulinum toxin revealed a statistically significant increase during the first 3.46 years of follow-up. In the long-term, a trend toward dose stabilization was identified. The median latency for the onset of effect was 4 days, while the median duration of effect was 3 months. All side effects were temporary, with the most common being hemifacial weakness (17.9%) and palpebral ptosis (3.3%). Most patients presented primary hemifacial spasm (88.1%), with a neurovascular conflict identified in 24.1% of cases.

Conclusion The increase in botulinum toxin dosage during the first years may be explained by dosage adjustment to control hemifacial spasm with the lowest possible doses. A prolonged interval between applications may also be associated with this increase. Dose stabilization tends to be achieved over time, indicating disease control.

Keywords

Hemifacial Spasm - Botulinum Toxins - Botulinum Toxins, Type A

Authors' Contributions

FMD: data curation, writing – original draft, writing– review & editing, and formal analysis; FOF: data curation, writing – original draft, writing– review & editing, and visualization; ADPN: data curation and writing – review & editing; COGJ: conceptualization, writing – original draft, writing – review & editing, and supervision; and RAS: conceptualization, writing – original draft, writing – review & editing, financial support, supervision, and data curation.


Support

The present study was supported financially by one of its authors (RAS).


Editor-in-Chief: Hélio A. G. Teive.


Associate Editor: José Luiz Pedroso.




Publikationsverlauf

Eingereicht: 29. Mai 2024

Angenommen: 15. September 2024

Artikel online veröffentlicht:
15. Januar 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

Bibliographical Record
Fátima de Menezes Dantas, Felipe Olobardi Freire, Agábio Diógenes Pessoa Neto, Clécio de Oliveira Godeiro Júnior, Rodrigo Alencar e Silva. Dosage of botulinum toxin in patients undergoing treatment for hemifacial spasm: is there modification during follow-up?. Arq Neuropsiquiatr 2025; 83: s00441793935.
DOI: 10.1055/s-0044-1793935
 

  • References

  • 1 Felicio AC, Godeiro-Junior Cde O, Borges V, Silva SM, Ferraz HB. Clinical assessment of patients with primary and postparalytic hemifacial spasm: a retrospective study. Arq Neuropsiquiatr 2007; 65 (3B): 783-786
    CrossrefPubMedSuche in Google Scholar
  • 2 Pandey S, Jain S. Clinical features and response to botulinum toxin in primary and secondary hemifacial spasm. Neurol India 2018; 66 (04) 1036-1042
    CrossrefPubMedSuche in Google Scholar
  • 3 Tambasco N, Filidei M, Nigro P, Parnetti L, Simoni S. Botulinum Toxin for the Treatment of Hemifacial Spasm: An Update on Clinical Studies. Toxins (Basel) 2021; 13 (12) 881
    CrossrefPubMedSuche in Google Scholar
  • 4 Lefaucheur JP. New insights into the pathophysiology of primary hemifacial spasm. Neurochirurgie 2018; 64 (02) 87-93
    CrossrefPubMedSuche in Google Scholar
  • 5 Duarte GS, Rodrigues FB, Castelão M. et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2020; 11 (11) CD004899
    CrossrefPubMedSuche in Google Scholar
  • 6 Jariyakosol S, Hirunwiwatkul P, Lerdlum S, Phumratprapin C. Prevalence and Associated Factors of Neurovascular Contact in Patients With Hemifacial Spasm. Asia Pac J Ophthalmol (Phila) 2015; 4 (04) 212-215
    CrossrefPubMedSuche in Google Scholar
  • 7 Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A. Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol 2009; 16 (03) 392-398
    CrossrefPubMedSuche in Google Scholar
  • 8 Cardoso Júnior JA. Aspectos clínicos, demográficos e neurocomportamentais em pacientes com espasmo hemifacial [dissertation]. Ribeirão Preto (SP): Faculdade de Medicina de Ribeirão Preto; 2018
    Suche in Google Scholar
  • 9 Silva RA. Desenvolvimento de modelo simulador facial para aquisição de habilidades manuais na técnica de aplicação de toxina botulínica no espasmo hemifacial e blefaroespasmo [dissertation]. Natal (RN): Universidade Federal do Rio Grande do Norte, Natal; 2022
    Suche in Google Scholar
  • 10 Barbosa ER, Takada LT, Gonçalves LR, Costa RM, Silveira-Moriyama L, Chien HF. Botulinum toxin type A in the treatment of hemifacial spasm: an 11-year experience. Arq Neuropsiquiatr 2010; 68 (04) 502-505
    CrossrefPubMedSuche in Google Scholar
  • 11 Batisti JP, Kleinfelder AD, Galli NB, Moro A, Munhoz RP, Teive HA. Treatment of hemifacial spasm with botulinum toxin type a: effective, long lasting and well tolerated. Arq Neuropsiquiatr 2017; 75 (02) 87-91
    Thieme ConnectPubMedSuche in Google Scholar
  • 12 Ledda C, Artusi CA, Tribolo A. et al. Time to onset and duration of botulinum toxin efficacy in movement disorders. J Neurol 2022; 269 (07) 3706-3712
    CrossrefPubMedSuche in Google Scholar
  • 13 Fowler FA, Yabumoto C, Osaki MH. et al. Profile of patients with essential blepharospasm and hemifacial spasm in the two largest ophthalmology reference centers in Brazil. Arq Bras Oftalmol 2023; 87 (06) e20220160
    CrossrefPubMedSuche in Google Scholar
  • 14 Dysport® (toxina botulínica A) [Internet]. São Paulo: Beaufour Ipsen Farmacêutica Ltda; 2023. [cited 2024 Aug. 23]. Available from: https://consultas.anvisa.gov.br/#/bulario/q/?numeroRegistro=116370143
    Suche in Google Scholar
  • 15 Botox® (toxina botulínica A) [Internet]. São Paulo: Allergan Produtos Farmacêuticos Ltda; 2024. [cited 2024 Aug. 23]. Available from: https://consultas.anvisa.gov.br/#/bulario/q/?nomeProduto=BOTOX
    Suche in Google Scholar
  • 16 Marchetti A, Magar R, Findley L. et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study. Mov Disord 2005; 20 (08) 937-944 Erratum in: Mov Disord. 2005 Aug;20(8):1089. Råuzizka, Evzen [corrected to Růzicka, Evzen]. PMID: 15810022
    CrossrefPubMedSuche in Google Scholar
  • 17 Ozer IS, Kuzu Kumcu M, Tezcan Aydemir S, Akbostanci MC. Dose conversion ratio, comparative efficacy, and adverse events after switching from onabotulinum toxin A to abobotulinum toxin A for neurological conditions. Clin Neurol Neurosurg 2021; 209: 106889
    CrossrefPubMedSuche in Google Scholar
  • 18 Brazil. Ministry of Health. Health Care Secretariat. Ordinance n. 1. It approves the Clinical Protocol and Therapeutic Guidelines for Dystonias and Hemifacial Spasm, of May 29, 2017. Available from: https://www.gov.br/conitec/pt-br/midias/protocolos/protocolo_uso/pcdt_distonias_e_espasmo_hemifacial_29_05_2017.pdf Accessed 2024; Aug 23
  • 19 Scaglione F. Conversion Ratio between Botox®, Dysport®, and Xeomin® in Clinical Practice. Toxins (Basel) 2016; 8 (03) 65
    CrossrefPubMedSuche in Google Scholar
  • 20 Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol 2014; 42 (03) 254-261
    CrossrefPubMedSuche in Google Scholar
  • 21 Ramirez-Castaneda J, Jankovic J. Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 2014; 90: 344-348
    CrossrefPubMedSuche in Google Scholar
  • 22 Gil Polo C, Rodríguez Sanz MF, Berrocal Izquierdo N. et al. Blepharospasm and hemifacial spasm: long-term treatment with botulinum toxin. Neurologia 2013; 28 (03) 131-136
    CrossrefPubMedSuche in Google Scholar
  • 23 Pérez-Saldaña MT, Parkhutik V, Boscá-Blasco ME, Claramonte B, Burguera-Hernández JA. Espasmo hemifacial: más de 10 años de tratamiento con toxina botulínica. Rev Neurol 2007; 45 (10) 582-586
    CrossrefPubMedSuche in Google Scholar
  • 24 Ramos VF, Karp BI, Lungu C, Alter K, Hallett M. Clinical Response to IncobotulinumtoxinA, after Demonstrated Loss of Clinical Response to OnabotulinumtoxinA and RimabotulininumtoxinB in a Patient with Musician's Dystonia. Mov Disord Clin Pract 2014; 1 (04) 383-385
    CrossrefPubMedSuche in Google Scholar
  • 25 Echeverría Urabayen A, Fanjul S, Meseguer E, García Ruiz Espiga PJ. Evolucion de la dosis de toxina botulinica tipo A en distonias craneocervicales. Estudio comparativo a lo largo de ocho años. Rev Neurol 2004; 38 (06) 511-513
    CrossrefPubMedSuche in Google Scholar
  • 26 Wang L, Hu X, Dong H. et al. Clinical features and treatment status of hemifacial spasm in China. Chin Med J (Engl) 2014; 127 (05) 845-849
    CrossrefPubMedSuche in Google Scholar
  • 27 Yaltho TC, Jankovic J. The many faces of hemifacial spasm: differential diagnosis of unilateral facial spasms. Mov Disord 2011; 26 (09) 1582-1592
    CrossrefPubMedSuche in Google Scholar
  • 28 Leong JL, Li HH, Chan LL, Tan EK. Revisiting the link between hypertension and hemifacial spasm. Sci Rep 2016; 6: 21082
    CrossrefPubMedSuche in Google Scholar
  • 29 Xu F, Gu P, Yuan H. et al. Analysis of risk factors related to the progression rate of hemifacial spasm. Front Neurol 2024; 15: 1357280
    CrossrefPubMedSuche in Google Scholar
  • 30 Colosimo C, Bologna M, Lamberti S. et al. A comparative study of primary and secondary hemifacial spasm. Arch Neurol 2006; 63 (03) 441-444
    CrossrefPubMedSuche in Google Scholar
  • 31 Batla A, Goyal C, Shukla G, Goyal V, Srivastava A, Behari M. Hemifacial spasm: clinical characteristics of 321 Indian patients. J Neurol 2012; 259 (08) 1561-1565
    CrossrefPubMedSuche in Google Scholar
  • 32 Herrero-Infante Y, Rodríguez-Sanz A, Máñez-Miró J, Vivancos-Matellano F. Hemifacial spasm through the last three decades: From etiology to efficacy and safety of long-term botulinum toxin treatment. Clin Neurol Neurosurg 2021; 203: 106555
    CrossrefPubMedSuche in Google Scholar
  • 33 Aktan D, Depierreux F. How to face the hemifacial spasm: challenges and misconceptions. Acta Neurol Belg 2024; 124 (01) 17-23
    CrossrefPubMedSuche in Google Scholar
  • 34 Chen SR. Neurological Imaging for Hemifacial Spasm. Int Ophthalmol Clin 2018; 58 (01) 97-109
    CrossrefPubMedSuche in Google Scholar
  • 35 Hermier M. Imaging of hemifacial spasm. Neurochirurgie 2018; 64 (02) 117-123
    CrossrefPubMedSuche in Google Scholar
  • 36 Yahalom G, Janah A, Rajz G, Eichel R. Therapeutic Approach to Botulinum Injections for Hemifacial Spasm, Synkinesis and Blepharospasm. Toxins (Basel) 2022; 14 (05) 362
    CrossrefPubMedSuche in Google Scholar
  • 37 Sorgun MH, Yilmaz R, Akin YA, Mercan FN, Akbostanci MC. Botulinum toxin injections for the treatment of hemifacial spasm over 16 years. J Clin Neurosci 2015; 22 (08) 1319-1325
    CrossrefPubMedSuche in Google Scholar
  • 38 Li YJ, Huang Y, Ding Q, Gu ZH, Pan XL. Evaluation of concentrations of botulinum toxin A for the treatment of hemifacial spasm: a randomized double-blind crossover trial. Genet Mol Res 2015; 14 (01) 1136-1144
    CrossrefPubMedSuche in Google Scholar